How does the immune system interact with Glioma cells in the brain?
The immune system's interaction with glioma cells is complex. Rather than being fully attacked, gliomas create a highly immunosuppressive microenvironment that helps them evade the body's defenses. This involves multiple cell types and signaling pathways that work together to protect the tumor. Understanding these interactions is key to developing effective immunotherapies.
What the research says
Gliomas actively remodel their microenvironment to suppress immune responses. A 2024 review explains that glioblastoma (the most aggressive glioma) accumulates myeloid-derived suppressor cells (MDSCs), glioma-associated macrophages/microglia (GAMs), and regulatory T cells (Tregs), which together inhibit anti-tumor immunity 9. MDSCs, though only 4-8% of immune cells in the tumor, are central to immune evasion and promote tumor growth 9. Another review highlights dynamic crosstalk between glioma cells and neurons, astrocytes, and immune cells that regulates tumor development 10.
Specific immune subtypes have been identified in gliomas. A study of 354 newly-diagnosed glioma patients (grades 2-4) found four immune subtypes: one with high antigen-presenting cells, one with high Tregs and myeloid cells but low effector lymphocytes, one with abundant effector lymphocytes, and one with low immune cells overall (associated with worse outcomes) 3. These subtypes show how variable the immune environment can be.
Ferroptosis, a form of cell death driven by iron, also plays a role. In the glioma microenvironment, CD8+ T cells release interferon-gamma (IFN-γ), which suppresses a key antioxidant protein (SLC7A11) in tumor cells, triggering ferroptosis and modulating anti-tumor immunity 1. This represents a potential mechanism by which the immune system can attack glioma cells.
Despite these immune attacks, gliomas often resist immunotherapy. A 2025 review notes that unique neural-immune interactions in the brain create challenges, including immune-suppressive crosstalk between brain, immune, and tumor cells 11. High tumor mutation burden (TMB) may improve outcomes with immune checkpoint inhibitors in some solid tumors, but its role in gliomas is still being studied 2.
What to ask your doctor
- What immune subtype does my glioma have, and does that affect treatment options?
- Are there any clinical trials targeting the immunosuppressive microenvironment in gliomas?
- How might ferroptosis-inducing therapies or immunotherapies be considered in my case?
- What is the role of tumor mutation burden in guiding immunotherapy for my glioma?
- Should I be evaluated for immune checkpoint inhibitors or other immunotherapies?
This question is drawn from common patient questions about Neurology and answered using cited medical research. We do not provide individualized advice.